Intuitive Surgical: Raising The Red Flag On The Hospital Industry

Aug. 23, 2022 11:23 AM ETIntuitive Surgical, Inc. (ISRG)JNJ, MDT23 Comments
North Post Research profile picture
North Post Research
400 Followers

Summary

  • Intuitive is a quality company with high recurring revenue and a flawless balance sheet.
  • The main consumer of the company's products, however, is fundamentally flawed and will be exposed by the recession.
  • It will get worse before it gets better for investors.

concentrated professional surgical doctor team operating surgery a patient in the operating room at the hospital. healthcare and medical concept.

Gumpanat

You wouldn't expect a company that controls 80% of its market, which is expected to grow at a 10% CAGR for the next decade, to be down 35% YTD, yet Intuitive Surgical (NASDAQ:ISRG) finds itself in this exact position. An abysmal quarter further amplified that major negative catalysts are beginning to take hold, forecasting more pain ahead.

Competitive Edge

Many know Intuitive as a surgical robotics company; we know it as an integrated ecosystem of health services.

Despite having a 20-year technological head start, the company wanted to prepare for competitors to eat away at market share. And so, management took a page out of Apple's (AAPL) playbook to combat the issue: create other services to trap customers.

Intuitive digital and data tools

J.P. Morgan Healthcare Conference

Its education and data analytics apps have shown strong growth, helping hospitals become increasingly efficient at surgeries. These tools make it easier and cheaper to purchase more da Vinci systems or its new Ion platform, a great selling point for that product.

Added features combined with regular maintenance costs have made Intuitive a recurring revenue powerhouse, accounting for 75% of revenues.

Intuitive recurring revenue

J.P. Morgan Healthcare Conference

Intuitive's sticky business model makes Johnson & Johnson's (JNJ) Ottava robot or Medtronic's (MDT) Hugo system irrelevant to them as existing consumers will likely continue to spend on their products because switching costs are too high.

Both competitors also announced that pricing will be comparable to the da Vinci machines, meaning management can use their pricing power and reputation to win over surgeons.

Having customer loyalty dramatically reduces the need for marketing expenditures, and with no debt on the balance sheet, gives Intuitive the flexibility to plow cash into R&D.

Intuitive r&d as a % of revenue

Author, Stock Analysis

In 2022, R&D as a % of Revenue is projected to reach an all-time high, a bullish sign as we know increased investments will translate to new revenue streams, helping the company distance itself from other players.

But if its moat is this wide, then it begs the question, what headwinds caused a dreary Q2 and a bleak outlook? For this, we must turn to Intuitive's only consumer: hospitals.

Negative Catalysts

Although the healthcare sector is often branded as recession-proof, healthcare equipment companies face downturns due to the poorly run privatized hospital industry.

To better understand the problem, we need to examine the 2010s carefully. Medical innovation was at its peak with biotechs on the rise and Intuitive's new da Vinci Xi machine released in 2014, leading patients to want the highest standard of care via new-age, expensive treatments. To meet demand, hospitals big and small began taking on long-term debt to afford medicines and surgeries, an action encouraged by record-low interest rates ripe for abuse.

Just look at Connecticut's hospital system. In FY 2011, medical facilities in Danbury, Hartford, Norwalk, and more were tripling debt into the billions only 3 years removed from the worst financial crisis in history. This robust appetite for debt only expanded through the decade, becoming the primary driver of growth. However, in today's macroeconomic backdrop, the financial leverage hospitals have been accumulating is finally being exposed.

Rate hikes have led to a drastic slowdown in borrowing, and the massive amounts of debt on the balance sheet means more cash must flow towards paying things down. Whatever money is not being used to become more financially stable, is going towards inflated expenditures. Over the past year, medical supplies have increased by 20.6% along with drug expenses going up 36.9% leading 1/3 of hospitals to have negative margins.

These ugly margins combined with massive amounts of debt leave minimal room for CapEx, including Intuitive's robotic machines. Hospitals aren't going to shell out $1.5M on a da Vinci system or $600K on an Ion platform and then spend $200K in annual maintenance and technology fees. We are seeing this problem unfold right in front of our eyes.

da Vinci system placements and y/y growth

Author, Intuitive Surgical Investor Relations

In the past quarter, the company posted a rare negative growth rate on systems placed, proving that 2021 was a fluke. Last year's high growth rate reflected a bounce back from COVID-19 disruptions and easy 2020 comps, masking the impact of a worsening economic situation.

Stretched Valuation

With impending headwinds on growth, bullish sentiment should take a backseat as the stock continues to undergo a necessary correction to better represent its current situation.

The market expects an earnings growth rate of 46.8% (FWD PEG of 4.68) when its actual earnings growth is no more than 10%, nearly 5x less. Overvaluation can also be seen in its forward P/S ratio of 13 which, excluding the past 2 years of ridiculously high metrics, is well above historical averages. Free cash flow is projected to be half of last year with a record low FCF yield of 1%, a distressing sign of a significant sales and profit slowdown.

Conclusion

As investors bottom feed for growth names, Intuitive proves as an excellent case study that some, even high-quality ones, are not done with their sell-off. However, strong company internals means it will be one to watch when the recession blows over in 6-8 quarters.

Editor's Note: This article was submitted as part of Seeking Alpha’s stock catalyst competition which runs through August 31. With cash prizes and a chance to chat with the CEO, this competition – open to all contributors - is not one you want to miss. Click here to find out more and submit your article today!

This article was written by

North Post Research profile picture
400 Followers
Fundamental analysis on growth and dividend equities with a focus on sustainability and ESG. We find innovative ideas that will generate long-term returns for investors' portfolios. To see the returns on each of our publications click here.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (23)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.